Boehringer Ingelheim HCP Survey: Nearly 20% of newly diagnosed lung cancer patients tested for EGFR mutations at risk of missing out on personalised treatments for their disease
Results from a new international survey of physicians revealed more patients with advanced non-small cell lung cancer (NSCLC) could benefit from targeted therapy based on their lung cancer type, over the use of chemotherapy. Test results to identify EGFR mutations were not available prior to deciding on therapy for nearly one in five (18%*) patients for whom a test was ordered. The goal of personalised therapy for all eligible patients remains out of reach for many, despite international guidelines which recommend molecular testing for EGFR mutation and ALK rearrangements in lung cancer patients at diagnosis, to guide treatment decisions. The survey results were presented today as a late-breaking abstract (P3.02b-023) at the 2016 World Conference on Lung Cancer (WCLC) in Vienna, Austria.
Dr. Vera Hirsh, medical oncologist in the Department of Medical Oncology at Royal Victoria Hospital in Montreal, and Professor at McGill University commented, “This survey highlights both encouraging and concerning results for the treatment of first-line non-small cell lung cancer patients. Whilst globally EGFR testing rates were on average high at 80%*, if physicians do not have access to ordered test results prior to first-line treatment this defeats the purpose of such testing. This survey helps us to observe an incomplete implementation of guidelines, which brings forth a significant area of need. Ensuring patients do not miss out on personalised treatment, which could greatly benefit outcomes, is key.”
The survey of 707 physicians in 11 countries (Canada, China, France, Germany, Italy, Japan, South Korea, Spain, Taiwan, UK, USA), sponsored by Boehringer Ingelheim, aimed to identify year-on-year improvements and changes in EGFR mutation testing rates and treatment practices in NSCLC, when compared to an inaugural survey in 2015.
In comparison to 2015, the number of tests ordered but not received prior to first-line treatment decreased (23% in 2015; 18%* in 2016), however treatment decisions were still made before knowing mutation status for one in five patients. Turnaround time for test results could be a key barrier. For the majority of patients tested for EGFR mutations, results were available within 10 business days. However approximately one test result out of every four globally (24%*) was received later, meaning treatment decisions were possibly delayed or not informed by mutation status.
“This international survey helps to bring the current advanced lung cancer treatment landscape into the spotlight, and interestingly track what has and hasn’t changed in the last year,” said Dr. Matthew Peters, Chair of the Global Lung Cancer Coalition (GLCC). “These patients can benefit from targeted treatments, but crucial steps in the treatment pathway are mutation testing in the first instance, receiving accurate test results in time to guide therapy, and understanding the different treatment benefits of available therapies. The key conclusion is that more is needed to support physicians in their goal to improve outcomes for EGFR mutation-positive patients.”
Further findings from the international survey showed that:
- Globally nearly four out of five (79%*) EGFR mutation-positive patients were treated first-line with tyrosine kinase inhibitors (TKIs) in 2016, consistent with 2015 (80%), with large country variances.
- Over half (51%*) of physicians did not differentiate between available EGFR targeted therapies. Recent data has helped physicians make informed treatment decisions between first- and second-generation TKIs.
- Over half (54%*) of physicians deemed prolonging of survival / extending life as the most important goal in first-line treatment, consistent with the primary goal reported in last year’s survey (63%).
- When asked what the most important treatment attribute was when choosing a first-line therapy, 54%* of physicians selected a clinically relevant increase in overall survival, followed by an increase in progression-free survival (18%*), strong improvement of health related quality of life (8%*) and meaningful overall response rate (ORR 8%*).
NSCLC is the most common form of lung cancer, which accounts for 80-85% of all lung cancer cases. EGFR mutation-positive NSCLC is a subtype of lung cancer. EGFR mutations are found in 10-15% of Caucasian and 40-50% of Asian patients with NSCLC. Often, lung cancer is diagnosed at a late stage (advanced) which can make it even more difficult to treat.
*Global figures excluding China.
Intended audiences: This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.
For references and notes to editors, please visit: http://www.boehringer-ingelheim.com/press-release/egfr-treatment-choices-global-survey
For more information, please visit: www.boehringer-ingelheim.com
Further media channels:
Media + PR
Phone: +49 6132 – 77 93319
Fax: +49 6132 – 77 6601
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
LTI USD Revenue Growth up 23.4% YoY; Net Profit Jumps 35.2% YoY23.7.2018 14:53 | Pressemelding
Larsen & Toubro Infotech (BSE: 540005, NSE: LTI), a global technology consulting and digital solutions company, announced its Q1 FY19 results today. In US Dollars: Revenue at USD 319.9 million; growth of 3.5% QoQ and 23.4% YoY Constant Currency Revenue growth of 5.1% QoQ and 22.9% YoY In Indian Rupees: Revenue at Rs 21,557 million; growth of 7.7% QoQ and 29.0% YoY Net Income at Rs 3,612 million; growth of 24.8% QoQ and 35.2% YoY “We are pleased to report a strong start to the year with 5.1% QoQ revenue growth in constant currency. Our growth has been driven by continued healthy momentum across multiple sectors, with double-digit sequential growth in BFS and High-Tech & Media in Q1. We are also happy to announce a large deal with a Global Fortune 100 consumer and pharmaceutical giant with a net-new TCV win in excess of US$ 50 Mn. “Our focus on leveraging digital technologies to solve the challenges of physical and digital convergence is resonating with our clients and has laid the found
TRIGO Deepens its Expansion into the USA by Acquiring Lumbee Enterprises23.7.2018 13:00 | Pressemelding
TRIGO has acquired 100% of the capital of Lumbee Enterprises based in Greer, SC. This acquisition allows TRIGO to deepen its expansion into the USA within the automotive industry. Lumbee began providing supply chain and logistics services over 25 years ago and it’s TRIGO’s intent to leverage Lumbee’s proven expertise to further expand its business. Lumbee is best known for its expertise in Quality Manufacturing, Sorting, Inspection and Sub-Assembly Operations, specializing in providing best-in-class inspection and rework services to keep OEM assembly lines running seamlessly and without interruption. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180723005040/en/ Co-founded by Colby Griffin in 2001, LUMBEE Enterprises of South Carolina has focused on providing quality management services to shorten supply chain interruptions through the innovative use of technology and processes. “This acquisition is a great opportunity for
STATS Taps Dr. Helen Sun, Former CTO of JPMorgan Chase Commercial Banking Division, to Lead STATS’ Technology Operations23.7.2018 11:00 | Pressemelding
Today, STATS, the worldwide leader in sports data and intelligence, expanded its executive roster with the introduction of Dr. Helen Sun as Chief Technology Officer. Sun will oversee STATS’ product, engineering, artificial intelligence and data production teams in developing the next generation of products and services that will revolutionize the performance and experience of sports. Sun joins STATS from JPMorgan Chase, most recently serving as Chief Technology Officer of the Commercial Banking division. For over 22 years, Sun has a proven record as a technology strategist and thought leader in previous roles as Vice President of Cloud Computing, Information Management, and Architecture at Motorola Solutions; Senior Director of Global Enterprise Architecture at Salesforce; and Director of Enterprise Architecture at Oracle. “Helen is a leader in transforming businesses through innovative solutions and she will be a driving force in building upon our reputation as the leading sports tech
IBC2018 Enhances Conference Programme with Keynote Sessions from Amazon, Viacom and Wonderhood Studios23.7.2018 10:57 | Pressemelding
IBC2018, the world’s most influential media, entertainment and technology show, today announces three new Keynote speakers from globally renowned media and entertainment powerhouses. The addition of executives from Amazon, Viacom and Wonderhood Studios adds to the big-name line up of thought provoking and informative sessions and speakers already announced by IBC. Taking to the stage on the first day of the conference, Thursday 13 September, to deliver the Trailblazer Keynote session entitled ‘Give Your Vision a Voice’ is Max Amordeluso, EU Lead Evangelist Amazon Alexa, Amazon. As voice assistants such as Amazon Alexa are transforming the way audiences discover content and control devices, Amordeluso’s must-attend presentation will explore a variety of avenues, including: how to build a voice strategy with Alexa; why voice experiences are now a crucial part of any multi-platform content business; how to implement an engaging voice strategy for content products and generate new revenues
SIGOS: Digital Experience - 120 mobile network operators from 60 countries meet in Nuremberg23.7.2018 10:06 | Pressemelding
For more than 10 years, SIGOS has been inviting mobile network operators from all over the world to the annual telecommunications conference. After venues such as Düsseldorf, Berlin, Munich, Beijing, Kuala Lumpur, etc., this year's multi-day conference took place at the Nuremberg convention centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180723005282/en/ SIGOS conference panel discussion - photo: www.uwe-niklas.com Over 120 network operators and telecommunications companies from over 60 countries worldwide came together to talk about the latest innovations in areas such as network quality, performance, 5G, IoT, roaming, and telecommunications fraud detection solutions. Dr. Ulrich Maly, Lord Mayor of the City of Nuremberg, welcomed the international audience in his opening speech and explained:"...when we talk about mobile communication, then we talk about people and their needs that are and should be the focus of atte
AURAK Enters into a Memorandum of Understanding with Al-Farabi Kazakh National University22.7.2018 09:52 | Pressemelding
The American University of Ras Al Khaimah (AURAK) President, Professor Hassan Hamdan Al Alkim, and the Al-Farabi Kazakh National University (KazNU) Rector, Professor Galimkair Mutanov, of the Republic of Kazakhstan, signed a Memorandum of Understanding (MoU), agreeing to exchange students, faculty, and research. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180722005025/en/ The Al-Farabi Kazakh National University (KazNU) Rector, Professor Galimkair Mutanov, of the Republic of Kazakhstan and the American University of Ras Al Khaimah (AURAK) President, Professor Hassan Hamdan Al Alkim, exchange a gift to commemorate their universities uniting in an MoU agreement. (Photo: AETOSWire) In the spirit of fostering a close international relationship between the Republic of Kazakhstan and the United Arab Emirates, developing bilateral relations in educational and scientific fields, and wishing to make their own contributions to the